McDowell, Heather P <br/><br/>
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.  [electronic resource] 

 -  International journal of cancer  Mar 2007 
 - 1141-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.22391  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily G, Member 2<br/>ATP-Binding Cassette Transporters--analysis<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Benzamides<br/>Cell Line, Tumor<br/>Drug Evaluation, Preclinical<br/>Humans<br/>Imatinib Mesylate<br/>Mice<br/>Mice, Nude<br/>Neoplasm Proteins--analysis<br/>Piperazines--therapeutic use<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-kit--analysis<br/>Pyrimidines--therapeutic use<br/>RNA, Messenger--analysis<br/>Receptors, Platelet-Derived Growth Factor--analysis<br/>Rhabdomyosarcoma--drug therapy<br/>Topotecan--therapeutic use<br/>Xenograft Model Antitumor Assays